An interventional study of Exercise + transcranial alternating current stimulation (Ex+tACS) and Control in Breast Cancer, sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Florida Atlantic University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the feasibility of a 4-week intervention combining exercise and transcranial alternating current stimulation (Ex+tACS) in breast cancer survivors who report experiencing cancer-related cognitive impairment. Feasibility will be assessed by measuring participant retention, adherence, satisfaction with the intervention, and safety. The researchers will also examine pre-to-post intervention changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).
Breast cancer is one of the most common forms of cancer among women in the United States. Although advances in cancer treatments have led to improved survival rates, breast cancer survivors must contend with the negative side effects from the cancer and its treatments. One of the most common and highly distressing treatment side effects is cancer-related cognitive impairment (CRCI), which is characterized by losses in memory, attention, processing speed, and executive function, which make daily tasks such as recalling information, organizing daily routines, concentrating, and multitasking more challenging. Findings from previous studies support aerobic exercise training as an effective strategy for improving cognitive function. In addition, non-invasive brain stimulation (NIBS), a technique in which electrodes are applied to the skin to noninvasively stimulate specific regions of the brain, has also been found to be a safe and effective approach for improving cognitive outcomes. Among various NIBS techniques, transcranial alternating current stimulation (tACS), which delivers current to the brain in an alternating pattern, may be a promising strategy for improving cognitive outcomes. Few studies have explored these approaches in breast cancer survivors, and to our knowledge, the combination of exercise and tACS (Ex+tACS) has not been explored.
This study will assess the feasibility of a 4-week Ex+tACS intervention in breast cancer survivors who report cancer-related cognitive impairment. Researchers will also examine changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's planned enrollment of 40 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Florida Atlantic University is the lead sponsor of 36 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Exercise + transcranial alternating current stimulation (Ex+tACS) group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS. During tACS, 6Hz alternating current stimulation will be administered to participants' prefrontal cortex (forehead region) using a tACS while the participant completes the AX Continuous Performance Test (AX-CPT).
Behavioral: Exercise + transcranial alternating current stimulation (Ex+tACS)
The Sham Comparator group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham transcranial alternating current stimulation (tACS) condition. The same procedures will be followed regarding the tACS, but stimulation will only last one minute, ramping up and down at the beginning and end of the 15-minute period, simulating the periodic tingling sensation that are reported with tACS.
Behavioral: Control
The Ex+tACS group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS while completing the AX Continuous Performance Test (AX-CPT).
The Control (CON) group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham tACS condition. After each session, both the EX+tACS and control participants will complete a questionnaire regarding experience with tACS.
Adherence
Adherence will be calculated based on the percentage of prescribed sessions attended and percentage of participants who complete the prescribed exercise and tACS sessions.
Time frame: From baseline to the end of the 4-week intervention
Retention
Retention will be determined by the number of enrolled breast cancer survivors who participate in the four-week intervention and complete post assessments.
Time frame: From baseline to the end of the 4-week intervention
Acceptability
Acceptability will be determined by the percentage of participants who report satisfaction with the intervention.
Time frame: From baseline to the end of the 4-week intervention
Safety (Adverse Events)
Safety (\<5% of serious adverse events) will be determined by the percentage of participants experiencing a serious adverse event related to the program.
Time frame: From baseline to the end of the 4-week intervention
Sustained attention
Researchers will assess pre- to post-intervention changes in sustained attention, measured by performance on the AX-Continuous Performance Test (AX-CPT).
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Executive function
Researchers will assess pre- to post-intervention changes in executive function, measured by performance (time) on the Trail Making Test Part A (TMT-A) and Part B (TMT-B).
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Inhibitory control
Researchers will assess pre- to post-intervention changes in inhibitory control, measured by performance on the Flanker Compatibility Task.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Working Memory
Researchers will assess pre- to post-intervention changes in working memory, measured by performance on the N-back and Backwards Counting tasks.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Subjective Cognition
Researchers will assess pre- to post-intervention changes in subjective cognition, measured by the Functional Assessment Cancer Therapy-Cognition (FACT-COG)
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function
Researchers will assess pre- to post-intervention changes in lower body physical function, measured by the 30-second chair stand.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Cardiorespiratory endurance
Researchers will assess pre- to post-intervention changes in cardiorespiratory fitness, measured by the six-minute walk test.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Body fat percentage
Researchers will assess pre- to post-intervention changes in body fat percentage measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Learning and Memory
Researchers will assess pre- to post-intervention changes in learning and memory, assessed by the California Verbal Learning Test.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Quality of Life (FACT-B)
Researchers will assess pre- to post-intervention changes in quality of life, measured by the Functional Assessment of Cancer Therapy - Breast. Scores range from 0-148, with higher scores indicating better quality of life.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fatigue (FACIT-F)
Researchers will assess pre- to post-intervention changes in fatigue, measured by the Functional Assessment of Chronic Illness Therapy-Fatigue. Scores range from 0-52, with higher scores indicating less fatigue.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Perceived exercise benefits and barriers
Researchers will assess pre- to post-intervention changes in perceived benefits and barriers to exercise, measured by the Exercise Benefits/Barriers Scale (EBBS). Benefit scores range from 29-116, with higher scores indicating greater perceived benefits. Barrier scores range from 14-56, with higher scores indicating greater perceived barriers.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function (Short Physical Performance Battery)
Researchers will assess pre- to post-intervention changes in physical function, assessed using the Short Physical Performance Battery. Scores range from 0-12, with higher scores indicating better physical function.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Muscle Power
Researchers will assess pre- to post-intervention changes in lower body muscle power, measured by a single sit-to-stand using the Tendo Power Analyzer.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Grip strength
Researchers will assess pre- to post-intervention changes in grip strength, measured using a hand-held grip strength dynamometer
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Upper body physical function
Researchers will assess pre- to post-intervention changes in upper body physical function, measured by the 30-second arm curl test.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fall Risk
Researchers will assess pre- to post-intervention changes in fall risk, measured by the Falls Efficacy Scale. Scores range from 16-64, with higher scores indicating greater fall risk.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Activity
Researchers will assess pre- to post-intervention changes in physical activity, measured by an accelerometer.
Time frame: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Skeletal Muscle
Description: Researchers will assess pre- to post-intervention changes in skeletal muscle (kg) measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device
Time frame: Baseline, within two weeks following the intervention, 4-week follow-up
Plan to share: Yes — The dissemination plan includes sharing de-identified data for external researchers.
Supporting information: Study protocol, Informed consent form
Time frame: IPD will be available at the time of manuscript acceptance and publishing. A published manuscript is planned for 2027.
Access criteria: Any external researcher will be able to access de-identified, non, PHI, individual participant data as part of the journal's supplementary information.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 11 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Florida Atlantic University